Can a breast cancer drug reach brain tumors? new study aims to find out
NCT ID NCT06058988
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how much of the drug T-DXd enters brain tumors in people with HER2-positive brain cancers or glioblastoma. Thirty participants will receive T-DXd before surgery to remove a brain tumor, and researchers will measure drug levels in the tumor. The goal is to see if T-DXd can effectively target these hard-to-treat cancers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Trastuzumab deruxtecan (T-DXd)
What this could lead to
If successful, this could show that T-DXd reaches brain tumors effectively, pointing toward a new treatment option for HER2-positive brain cancers.
What could go wrong
This is a small, early-phase study focused on drug penetration, not yet proving the drug works. Results may not lead to a treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
RECRUITINGNew York, New York, 10065, United States
Contact Phone: •••-•••-••••